New Enterprise Associates, which invested $2.3 million in Sunesis Pharmaceuticals Inc. during a recent private placement, put Helen Kim on the Sunesis board.
Kim is CEO of TRF Pharma Inc., a privately held business. In the past she was president and CEO of Kosan Biosciences Inc., which was sold to Bristol-Myers Squibb (NYSE: BMY) in 2008.
She also worked previously for Chiron Corp., Protein Design Labs, Affymax and Onyx Pharmaceuticals.
Dan Swisher is CEO of South San Francisco-based Sunesis (NASDAQ: SNSS).
Earlier this month Johnson & Johnson Pharmaceutical Research & Development LLC terminated a research deal between the two that dates back to May 3, 2002. Though Sunesis was paid some money up front and through 2005 under that deal, it hadn’t been paid anything since December 2005.
Johnson & Johnson gave 180 days notice, so that deal ends Jan. 13, 2010.
No comments:
Post a Comment